FDA Seeks Feedback on Scary Cigarette Pack Warnings
Published Date: 12/19/2025
Notice
Summary
The FDA wants your thoughts on how they collect info about cigarette warning labels on packs and ads. This affects tobacco companies who must follow these rules and helps keep smokers informed. You’ve got until February 17, 2026, to share your comments—no cost to you, just your voice!
Analyzed Economic Effects
5 provisions identified: 2 benefits, 3 costs, 0 mixed.
Pre‑Approval Cigarette Plan Requirement
If you are a tobacco product manufacturer, you must submit a cigarette plan to FDA and get FDA approval before displaying or distributing cigarette packages or advertisements. Plans must show how required warnings will be randomly and equally displayed on packaging and rotated quarterly in advertising.
Time Burden for Plan Submissions
FDA estimates up to 17 entities will submit initial cigarette plans each year, taking an average of 150 hours per initial plan, and about 8 supplements per year at 75 hours each. FDA estimates total annual reporting hours of 3,150 and a total annual burden (reporting + recordkeeping) of 3,981 hours.
Recordkeeping and 4‑Year Retention Rule
Manufacturers must keep a copy of the FDA‑approved cigarette plan while it is in effect and for at least 4 years after it was last in effect, and that copy must be available for FDA inspection and copying. FDA estimates 51 recordkeepers will keep about 77 records at 3 hours per record for 231 hours annually.
Public Comment Opportunity Deadline
You can submit electronic or written comments on this FDA information‑collection notice to docket FDA‑2025‑N‑6076 by February 17, 2026, using https://www.regulations.gov or by mail; there is no fee to comment. Comments received by that date will be placed in the public docket.
Mandatory Warnings on Packs and Ads
Cigarette packages and advertisements must bear one of 11 textual warning statements accompanied by color graphics depicting the negative health consequences of smoking; the final rule implementing this was published March 18, 2020, with an effective date of June 18, 2021. These warnings are required under the Federal Cigarette Labeling and Advertising Act and FDA's implementing regulation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-23473 — Sentencing Guidelines for United States Courts
The United States Sentencing Commission is updating the rules judges use to decide punishments in federal courts. These changes could affect people facing sentencing by possibly changing how past and future cases are handled. The public can share their thoughts by February 10, 2026, and a hearing might be held to discuss the updates.
Next: 2025-23475 — Timothy Balisky, N.P.; Decision and Order
Timothy Balisky, a nurse practitioner from North Carolina, lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of July 31, 2025. This means he can’t prescribe or manage controlled drugs anymore, affecting his professional practice and patients relying on him.